Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial

Marazzi, Giuseppe; Pelliccia, Francesco; Campolongo, Giuseppe; Cacciotti, Luca; Massaro, Rosalba; Poggi, Sara; Tanzilli, Alessandra; Iorio, Martina Di; Volterrani, Maurizio; Lainščak, Mitja

doi:10.1016/j.ijcard.2016.07.163

Cited by 12 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This field is continuously enriched with new products of synthesis, semi-synthesis or extraction even if the number of pharmaceuticals is very large. Nowadays pharmaceutical industry has set out to focus on cutting edge research areas that includes nanotechnology [5,6].…”

mentioning

confidence: 99%

Evaluation of AML-VAL Nanoparticles as Combined Therapy in Cardiovascular Disease

Sha’at¹,

Pavaloiu²,

Salceanu³

et al. 2018

Mat.Plast.

View full text Add to dashboard Cite

The main aim of this study was to investigate a mixture of two poorly water-soluble active pharmaceutical ingredients (APIs): an angiotensin II receptor antagonist (valsartan) and a calcium channel blocker (amlodipine besylate), chosen in a fixed-dose, in order to obtain new polymeric nanoparticles (NPs) for cardiovascular diseases treatment. NPs were prepared via nanoprecipitation method using poly (D,L-lactide-co-glycolide) (PLGA) as matrix and Pluronic F127 as stabilizer. Three formulations were investigated with different ratios of AML:VAL:PLGA (1:16:5, 1:16:7.5 and 1:16:10). Particle size, polydispersity index and zeta-potential analyses were performed to characterize and optimize the formulation. The in vitro drug release study was determined by using a dialysis membrane method under sink conditions. All NPs loaded with both APIs showed nano-size, negative potential, a high homogeneity and a slow drugs release in physiological environment.

show abstract

mentioning

confidence: 99%

Evaluation of AML-VAL Nanoparticles as Combined Therapy in Cardiovascular Disease

Sha’at¹,

Pavaloiu²,

Salceanu³

et al. 2018

Mat.Plast.

View full text Add to dashboard Cite

show abstract

“…Compliance was significantly greater in the fixed group vs. the free group (94% vs. 85% respectively, p = 0.034). There were no statistically significant differences between diastolic blood pressure, LDL-C level and adverse events [11].…”

Section: Discussionmentioning

confidence: 72%

Ocena skuteczności leczenia hipotensyjnego pacjentów z nadciśnieniem tętniczym i chorobą niedokrwienną serca lub ekwiwalentem wieńcowym

Ryś

Paluch²,

Semczuk

et al. 2017

Arterial Hypertension

View full text Add to dashboard Cite

Introduction. Arterial hypertension (AH) is a well-known cardiovascular risk factor. Currently, in Poland, approximately 32% of adults suffer from AH, and only 26% of them are treated successfully. The study aims to determine the incidence of atherosclerosis risk factors and their influence on the effectiveness of hypotensive treatment in the population of patients with AH and coexisting coronary artery disease (CAD) or coronary equivalent. Material and methods. The study included 204 adults. The inclusion criteria were: diagnosis of AH with coexisting a diagnosis of CAD (138 people) or coronary equivalent defined as high (≥ 5%) atherosclerosis-related risk of death in 10-year prognosis, estimated using the EURO SCORE scale (66 people). During observation, pharmacological and nonpharmacological treatments were modified according to the current AH treating standards. After 6 months of observation, the effectiveness of AH control was assessed. Results. Multivariate logistic regression analysis revealed that main factors affecting poor blood pressure control after six months of observation were: obesity, age > 65 years, LDL cholesterol level > 130 mg/dL. Moreover, systolic blood pressure (SBP) < 140 mmHg was more frequent in patients with diabetes mellitus. After six months of therapy, good control of SBP was found in 42.7% of patients and normal values of diastolic blood pressure (DBP) -in 65.2 % of patients. Conclusion. Independent risk factors for poor control of blood pressure were: high level of LDL-cholesterol, age > 65 years and female sex. Paradoxically, diabetes was not a risk factor for poor control of hypertension. The introduction of combined hypotensive and lipid-lowering drugs should contribute to a better control of hypertension in Poland. key words: risk factors; arterial hypertension; treatment efficacy

show abstract

“…5,6 Given the large number of patients who have both hypertension and hypercholesterolemia as well as the increased cardiovascular risk that results from their coexistence, several studies evaluated the safety and efficacy of fixed-dose combinations of atorvastatin and up to three different antihypertensive agents. [7][8][9][10] All these studies showed that fixed-dose combinations result in similar reductions in blood pressure (BP) and LDL-C levels compared with separate pill regimens. [7][8][9][10] In contrast, there are limited data regarding the effects on BP and LDL-C levels of fixed-dose combinations of rosuvastatin and antihypertensive agents.…”

Section: Hypertension and Elevated Low-density Lipoprotein Cholesterolmentioning

confidence: 99%

“…[7][8][9][10] All these studies showed that fixed-dose combinations result in similar reductions in blood pressure (BP) and LDL-C levels compared with separate pill regimens. [7][8][9][10] In contrast, there are limited data regarding the effects on BP and LDL-C levels of fixed-dose combinations of rosuvastatin and antihypertensive agents. [11][12][13] Since rosuvastatin induces the largest reductions in LDL-C levels among statins, including this agent in a fixed-dose combination with antihypertensive agents might represent a useful tool in achieving LDL-C targets, particularly in high-risk patients.…”

Section: Hypertension and Elevated Low-density Lipoprotein Cholesterolmentioning

confidence: 99%

“…15 The findings of the study by Kim et al further strengthen the results of previous studies, which showed that fixed-dose combination of statins and antihypertensive agents is similarly effective and safe with monotherapy. [7][8][9][10][11][12][13]15 It is well-established that despite the availability of several effective and safe classes of antihypertensive agents, less than one third of patients with treated hypertension have controlled blood pressure. 3 Accordingly, among patients with hypercholesterolemia who are receiving lipid-lowering treatment, LDL-C targets are achieved in approximately two thirds of patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Fixed‐dose combinations of lipid‐lowering and antihypertensive agents: The way forward?

Sofogianni

Τζιόμαλος

2020

J of Clinical Hypertension

View full text Add to dashboard Cite

Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial

Cited by 12 publications

References 12 publications

Evaluation of AML-VAL Nanoparticles as Combined Therapy in Cardiovascular Disease

Evaluation of AML-VAL Nanoparticles as Combined Therapy in Cardiovascular Disease

Ocena skuteczności leczenia hipotensyjnego pacjentów z nadciśnieniem tętniczym i chorobą niedokrwienną serca lub ekwiwalentem wieńcowym

Fixed‐dose combinations of lipid‐lowering and antihypertensive agents: The way forward?

Contact Info

Product

Resources

About